Objective  To explore effect of amisulpride on score of Positive and Negative Syndrome Scale (PANSS), prolactin (PRL) level, body mass and quality of life in patients with schizophrenia.

  Methods  Totally 80 schizophrenia patients were randomly divided into control group (n=40) and observation group (n=40). The control group was given risperidone, while observation group was given amisulpride. The clinical efficacy, score of PANSS, PRL level, body mass, score of short-form health survey (SF-36) and incidence rate of adverse reactions were compared between the two groups.

  Results  There was no significant difference in the total effective rate between the two groups (P>0.05). After treatment, the score of negative symptoms and total score in the observation group were significantly lower than those in the control group (P < 0.05), while there were no significant differences in the scores of positive symptoms and psychopathological status between the two groups (P>0.05). After treatment, the PRL level in the observation group was significantly lower than that in the control group (P < 0.05), and there was no significant difference in body mass between the two groups (P>0.05). After treatment, the scores of general health, social function, emotional function and body function in the observation group were significantly higher than those in the control group (P < 0.05). There were no significant differences in the scores of physiological function, physical pain, vitality and mental health between the two groups (P>0.05). The incidence rate of adverse reactions in the observation group was 10.00%, which was significantly lower than 30.00% in the control group (P < 0.05).

  Conclusion  Amisulpride and risperidone have the same effect in treating schizophrenia patients, but the effect of amisulpride on negative symptoms is better, and it can reduce PRL level and improve the quality of life.